Your browser doesn't support javascript.
loading
Epidemiology of moderately severe and severe non-proliferative diabetic retinopathy in South West England.
Nevill, Clareece R; Stratton, Irene M; Maruti, Sonia S; Massó-González, Elvira L; Sivaprasad, Sobha; Bailey, Clare; Ehrlich, Michael; Chong, Victor; Scanlon, Peter H.
Afiliação
  • Nevill CR; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK.
  • Stratton IM; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK.
  • Maruti SS; Boehringer Ingelheim Pharmaceuticals Incorporated, Fremont, CA, USA.
  • Massó-González EL; Boehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
  • Sivaprasad S; Moorfields Eye Hospital, London, UK.
  • Bailey C; Bristol Eye Hospital, Bristol, UK.
  • Ehrlich M; Boehringer Ingelheim Pharmaceuticals Incorporated, Fremont, CA, USA.
  • Chong V; Boehringer Ingelheim International GmBH, Ingelheim am Rhein, Germany.
  • Scanlon PH; Gloucestershire Retinal Research Group, Cheltenham General Hospital, Cheltenham, UK. p.scanlon@nhs.net.
Eye (Lond) ; 36(2): 433-440, 2022 02.
Article em En | MEDLINE | ID: mdl-33692539
ABSTRACT

AIMS:

To estimate the incidence of early treatment diabetic retinopathy study (ETDRS) level 47 and 53 and progression to treatment with panretinal photocoagulation (PRP) for proliferative DR (PDR).

METHODS:

Log-linear regression was used to estimate the incidence of level 47-53 or worse for 33,009 people with diabetes (PWD) in Gloucestershire during 2013-2016 by calendar year and diabetes type, based on the first recording. Progression was analysed in Gloucestershire and Bristol with a parametric survival analysis examining the association of baseline and time-varying demographic and clinical factors on time to PRP after the first recording of level 47-53.

RESULTS:

Incidence decreased from 0.57 (95% confidence intervals (CI) 0.48-0.67) per 100 PWD in 2013 to 0.35 (95% CI 0.29-0.43) in 2016 (p < 0.001). For progression, 338 eligible PWD from Gloucestershire and 418 from Bristol were followed for a median of 1.4 years; 78 and 83% had Type 2 diabetes and a median (interquartile range) of 15 (10-22) and 17 (11-25) years duration of diagnosed diabetes respectively. Three years from the incident ETDRS 47-53, 18.9% and 17.2% had received PRP respectively. For Gloucestershire, severe IRMA and updated mean HbA1c were associated with an increase in the risk of initiating PRP (hazard ratio 3.14 (95% CI 1.60-6.15) and 1.21 (95% CI 1.06-1.38 per 10 mmol/mol) respectively).

CONCLUSION:

This study provides additional understanding of this population and shows that a high proportion of patients with ETDRS levels 47-53 need to be monitored as they are at high risk of progressing to PDR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Retinopatia Diabética Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Eye (Lond) Assunto da revista: OFTALMOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Retinopatia Diabética Tipo de estudo: Diagnostic_studies / Incidence_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Eye (Lond) Assunto da revista: OFTALMOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido